Cabozantinib, a dual MET/VEGFR2 inhibitor, was assessed in a phase II clinical trial for CCA patients but exhibited significant toxicity and failed to demonstrate meaningful antitumor activity (mPFS: 1.8 months, mOS: 5.2 months) (Supplementary Table S1) [100]. Here, MET is linked to cholangiocarcinoma.